Vimang®

5 trials

Sponsors

Center of Pharmaceutical Chemistry

Conditions

AgingDermatitis Chronic diseaseDiabetes mellitus Type 1Ischemic strokeSpinocerebellar Hereditary Ataxia Type 2

Phase 2

Evaluation of the antiinflammatory effect of the Vimang® cream in patients with Dermatitis chronic disease.

Active, not recruitingRPCEC00000001

Center of Pharmaceutical ChemistryDermatitis Chronic disease

Start: 2007-03-18Target: 30Updated: 2026-03-30

Effect of the supplementation with Vimang ® on indicators of oxidative stress in young people with Diabetes Mellitus type 1.

Active, not recruitingRPCEC00000002

Center of Pharmaceutical ChemistryDiabetes mellitus Type 1

Start: 2008-01-15Updated: 2026-03-30

Extract of Mangifera indica L. (Vimang®)- Third age- Phase II.

Active, not recruitingRPCEC00000003

Center of Pharmaceutical ChemistryAging

Start: 2007-11-15Target: 64Updated: 2026-03-30

Extract of Mangifera indica L. (Vimang®)-Ischemic Stroke

Active, not recruitingRPCEC00000004

Center of Pharmaceutical ChemistryIschemic stroke

Start: 2008-03-17Target: 120Updated: 2026-03-30

Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2

Active, not recruitingRPCEC00000005

Center of Pharmaceutical ChemistrySpinocerebellar Hereditary Ataxia Type 2

Start: 2008-03-30Target: 20Updated: 2026-03-30